Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer
One in two women with advanced ovarian cancer has an HRD-positive tumor
One in two women with advanced ovarian cancer has an HRD-positive tumor
The campaign will also focus on providing doorstep TB screening services to facilitate diagnosis
This will give a boost to cost-effective, quality medicines and contribute towards reduction in out of pocket expenditure on healthcare for the citizens
If implemented across the world, it has the capability to save over 100,000 lives annually
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
The virtual event will be attended by representatives from state & district health administration, corporates, industries, civil society, and NGOs as the country reiterates its commitment towards TB elimination by 2025
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Subscribe To Our Newsletter & Stay Updated